Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
J Korean Med Sci. 2022 Aug 1;37(30):e233. doi: 10.3346/jkms.2022.37.e233.
The World Health Organization declared coronavirus disease 2019 (COVID-19) a global pandemic in March 2020. Several vaccines have been developed to overcome the COVID-19 pandemic, and messenger RNA vaccines, commonly known as mRNA vaccines, were the first COVID-19 vaccines to be authorized in Korea. With the worldwide increase in vaccinations, reports of adverse reactions are increasing. However, to the best of our knowledge, there have been no reports of eosinophilic gastroenteritis (EGE) following mRNA vaccination. Here, we present the first case of EGE in a patient who received a second dose of the mRNA vaccine, BNT162b2 (Pfizer-BioNTech). A previously healthy 34-year-old woman presented to the emergency department with generalized abdominal pain for the preceding 2 weeks. She had received a second dose of the mRNA COVID-19 vaccine 2 weeks prior. Subserosal EGE was diagnosed, oral prednisolone was administered, and she recovered completely.
世界卫生组织于 2020 年 3 月宣布 2019 年冠状病毒病（COVID-19）为全球大流行。为了克服 COVID-19 大流行，已经开发出几种疫苗，信使 RNA 疫苗，通常称为 mRNA 疫苗，是在韩国首次获得授权的 COVID-19 疫苗。随着全球范围内疫苗接种的增加，不良反应报告也在增加。然而，据我们所知，mRNA 疫苗接种后没有嗜酸细胞性胃肠炎（EGE）的报告。在这里，我们报告了首例接受 mRNA 疫苗（BNT162b2[辉瑞-生物科技]）第二剂接种的患者的 EGE 病例。一名 34 岁既往健康的女性因前 2 周出现全腹疼痛而到急诊就诊。她在 2 周前接种了第二剂 mRNA COVID-19 疫苗。诊断为黏膜下 EGE，给予口服泼尼松龙，她完全康复。
